
Lilly agrees to buy U.S. biotech Morphic in US$3.2 billion deal
BNN Bloomberg
Eli Lilly & Co. agreed to buy U.S. biopharma company Morphic Holding Inc. for about US$3.2 billion to gain experimental therapies for inflammatory bowel disease and other chronic illnesses.
More Related News

U.S. President Donald Trump on Monday said the U.S. was talking with a “respected” Iranian leader and claimed the Islamic Republic was eager for a deal to end the war. He also extended a deadline for Iran to reopen the crucial Strait of Hormuz or face attacks on its power plants, saying it has an additional five days.












